of the acceptable upper limit of 10 seconds whereas the disintegration time of the dosage form containing paracetamol and citric acid was a very acceptable time of 3 10 seconds without an unacceptable loss of tensile strength while the disintegration time for the dosage form containing piroxicam was shortened when citric acid was present it will be noted that the disintegration time in the absence of citric acid was still acceptable following a similar procedure to that described in the previous examples solid dosage forms containing 400 mg of paracetamol were produced using the ingredients listed in table 3 below the results shown in table 4 indicate that solid dosage forms containing a 400 mg dose of paracetamol can be produced successfully and that reducing the gelatin level from 1 5 to 0 75 by weight and the mannitol level from 1 13 to 0 55 w w did not have a very marked effect on the disintegration time following a procedure similar to that described in examples 1 and 2 solid dosage forms containing 10 wt of rofecoxib substantially water insoluble 0 004 mg ml were produced using the ingredients listed in table 5 the results of testing are listed in table 5 below it will be seen from table 5 that the disintegration times are considerably reduced as compared with dosage forms which do not contain added acid without significant effect on tensile strength solid fast dispersing pharmaceutical dosage forms have many desirable attributes however they also have various shortcomings the present invention provides a method of production that solves the problems of increased disintegration times when high loadings of low water solubility drugs are used this discovery advances the state of the art in the preparation of fast dispersing pharmaceutical dosage forms in the.